Eurobio Scientific S.A.
ALERS.PA · PAR
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -6.95 | -0.47 | -0.14 | -0.32 |
| FCF Yield | 5.20% | 12.39% | 18.74% | 21.78% |
| EV / EBITDA | 13.29 | 9.56 | 6.77 | 2.70 |
| Quality | ||||
| ROIC | 3.94% | 2.52% | 8.99% | 34.27% |
| Gross Margin | 46.44% | 44.00% | 42.62% | 52.75% |
| Cash Conversion Ratio | 4.18 | 5.54 | 1.68 | 1.08 |
| Growth | ||||
| Revenue 3-Year CAGR | 0.51% | -10.90% | -6.86% | 45.90% |
| Free Cash Flow Growth | -40.80% | -41.78% | -38.67% | 22.30% |
| Safety | ||||
| Net Debt / EBITDA | 0.60 | 2.09 | 1.63 | -0.97 |
| Interest Coverage | 2.39 | 2.29 | 23.97 | 158.21 |
| Efficiency | ||||
| Inventory Turnover | 3.08 | 3.41 | 4.04 | 5.36 |
| Cash Conversion Cycle | 129.10 | 111.27 | 108.89 | 90.39 |